Aegicare
Aegicare is a national high-tech enterprise in China that leverages AI for precision diagnosis and treatment in the clinical field, owning significant intellectual property and partnerships with top institutions.
Company Overview
Aegicare is a national high-tech enterprise focused on AI-empowered clinical precision diagnosis and treatment. The company owns Shenzhen Anjikang'er Medical Laboratory, a wholly-owned subsidiary, and provides comprehensive clinical whole-genome solutions for patients, medical institutions, and research organizations. Aegicare is committed to advancing intelligent precision medicine in China.
Technological Platforms
Aegicare has developed two key technological platforms: the AEGIS™ Genomic Intelligence Platform and the WEAVER™ bioinformatics analysis system. These platforms are designed to provide precision and efficient bioinformatics analysis and genetic interpretation services, particularly for rare diseases. The company's innovative solutions have had a significant impact in the field of genetic research and diagnostics.
Medical Laboratory
Aegicare operates a 1500 square meter medical laboratory that has received approval from the Health Commission. This facility is equipped to carry out a wide range of diagnostic tests and analyses, supporting the company's mission to deliver precision diagnostics. The laboratory plays a crucial role in the implementation and development of Aegicare's clinical solutions.
Strategic Partnerships
Aegicare has established long-term strategic partnerships with over 300 top-tier hospitals across China. These collaborations enhance the company's capabilities in delivering precision diagnostic services. Additionally, Aegicare works closely with academic institutions such as Peking University College of Engineering and Tongji Medical College of Huazhong University of Science and Technology, furthering their advancements in intelligent precision medicine.
Intellectual Property
Aegicare holds over 100 intellectual property rights, underscoring its commitment to innovation and leadership in the field of precision medicine. These intellectual properties cover various aspects of their technological platforms and diagnostic solutions, ensuring the company's proprietary advancements remain protected and exclusive.